Background
==========

Secondary hyperparathyroidism (sHPT) is a common complication of chronic kidney disease. Parathyroidectomy (PTX) is necessary in a substantial number of patients \[[@B1]-[@B4]\].

Previous studies reported wide variations in incidence of PTX over time \[[@B1]-[@B3],[@B5]\] Younger age, female gender, absence of diabetes, longer time on dialysis \[[@B1],[@B2],[@B4],[@B5]\] and lack of transplant \[[@B4]\] were all associated with an increased risk of PTX. However, as far as we know, no study has as yet investigated risk factors and rates of PTX in a country's entire population of patients on renal replacement therapy (RRT), comprising peritoneal, hemodialysis and transplant patients, after the introduction of current medical therapy for sHPT. Our aim was to investigate the incidence, regional distribution and factors associated with PTX as well as possible temporal changes, in the Swedish dialysis and transplant population.

Methods
=======

This study included data from three prospective, population based, national registries. The Swedish Renal Registry, SRR \[[@B6]\], provided the patient cohort, whereas PTXs were identified in the Swedish National Inpatient Registry (SNIR), run by the Swedish National Board of Health and Welfare \[[@B7]\] and the Scandinavian Quality Register for Thyroid Parathyroid and Adrenal Surgery (SQRTPA), \[[@B8]\].

Ethical approval
----------------

The study was approved by the Regional Ethics Committee of Lund, DNR 2010/483.

Patient cohort
--------------

All patients included in the SRR between 1^st^Jan 1991 and 31^st^dec 2009 (n = 20,056) were eligible for the present study. The SRR is a national web-based quality registry for patients on maintenance RRT \[[@B9]\].

Out of 20,056 eligible patients, we excluded 13 patients due to errors in reporting. Thus, the patient cohort consisted of 20,043 patients.

The pharmaceutical company Amgen (Solna, Sweden) provided aggregate data on the sales of cinacalcet (Mimpara®) per calendar year in Sweden.

Parathyroidectomy data
----------------------

PTX was identified through linkage between the SRR cohort and SNIR, and between the SRR and the (SQRTPA), by using the national personal identification number.

SNIR has been validated, with overall good to excellent results regarding accuracy of coding \[[@B10]\].

A total of 954 PTX were identified by the following in-hospital codes within the admission data: extirpation of parathyroid gland, BBA30 *or* 0851, subtotal parathyroidectomy, BBA40 *or* 0852, total parathyroidectomy, *BBA50 or 0853*, implantation or transplantation of parathyroid gland, BBA70 *or* 0870, and any other operation on parathyroid gland*,* BBA99 *or* 0898.

SQRTPA was launched in 2004 and the coverage 2010 was 90%. In general, less than five percent of patients were not registered or incorrectly registered. In this registry, 128 PTX were identified. Of these, 126 were also found among the hospital admission data. A total of 956 PTX were identified. We defined an incident PTX as the first PTX occurring after registration in the SRR. Out of the 956 PTX, 229 were performed before registration in the SRR. Of the remaining 727 PTX, 41 were in patients with two operations, and 7 in patients with three operations, during the study period. Thus we found a total of 679 incident PTX.

Determination of time-at-risk and follow-up
-------------------------------------------

Start date was defined as date of registration in the SRR. Patients were censored at death, at PTX, when lost to follow-up, or at end of study. To be able to correct for the impact of renal transplantation on the risk for PTX, we used time spent with functioning transplant prior to censoring as a time-dependent covariate. The cumulative sum of time spent with a functioning transplant in all transplant episodes was calculated. The term zero time with a functioning graft was used for patients who never received a transplant or in whom the transplant failed to function at start. Time with transplant was divided into four categories: 0, 0--1 year, 1--3 years and \>3 years. Due to censoring at time of entry a further 28 patients were excluded from statistical analysis.

Statistical analysis
--------------------

Means and standard deviations were used for continuous variables, and column percent for categorical variables. Time at risk in person-years was calculated for different categories of age, geographical region of treatment, cause of renal disease, and time with functioning graft, stratified by gender. The crude PTX rate was defined as the total number of PTX, divided by the total number of person- years. This was presented in various categories and stratified by gender. Poisson regression was used to estimate both unadjusted and adjusted incidence rate ratios. The model was adjusted for calendar year, gender, age, geographical region of treatment, cause of renal disease, and time with functioning graft. The PTX rate was divided into calendar years, with year 2000 as the reference year to evaluate the change in PTX incidence over time. The Poisson model goodness of fit was evaluated by comparison with negative binomial models. Unadjusted, aggregate sales of cinacalcet were graphically compared to unadjusted PTX rates for the years 2005--2009.

Results
=======

Patient characteristics at baseline are shown in Table [1](#T1){ref-type="table"}. A total of 679 PTX were identified in 20,015 patients (3.4%). The mean follow-up (SD) time for the whole cohort was 3.9 (4.1) years. The overall unadjusted PTX rate in 77,624 person-years of follow-up was 8.8 incident PTX per 1000 person-years at risk (95% CI: 8.1-9.4), Table [2](#T2){ref-type="table"}.

###### 

Baseline characteristics in the Swedish dialysis- and transplant population

  **Characteristics**                  **Cohort**    **Parathyroidectomy**                                            
  ----------------------------------- ------------- ----------------------- ------------- ------------- ------------- -------------
  Age at baseline, years               62.8 (16.5)        63.1 (16.4)        62.2 (17.0)   50.3 (14.7)   50.2 (14.5)   50.4 (14.9)
  Age at parathyroidectomy, years          \-                 \-                 \-        54.3 (14.0)   54.3 (13.9)   54.3 (14.2)
  Region                                                                                                                     
    North                                *10.8*             *10.8*             *10.7*         *5.7*         *5.4*         *6.1*
    Stockholm                            *17.8*             *17.1*             *18.9*        *17.1*        *15.3*        *18.8*
    South-east                           *11.8*             *12.0*             *11.5*        *11.2*        *10.5*        *11.9*
    South                                *18.3*             *19.0*             *16.9*        *21.4*        *22.8*        *20.0*
    Uppsala/Örebro                       *23.4*             *23.2*             *23.7*        *21.7*        *24.0*        *19.4*
    West                                 *17.6*             *17.5*             *17.8*        *22.5*        *21.3*        *23.7*
    Abroad                                *0.4*              *0.4*              *0.5*         *0.4*         *0.6*         *0.3*
  Cause of renal disease                                                                                                     
    Diabetes                             *24.2*             *23.9*             *24.8*        *14.9*        *14.1*        *15.6*
    Nephrosclerosis                      *18.2*             *20.6*             *13.9*        *10.0*         *9.6*        *10.4*
    Glomerulonephritis                   *15.9*             *17.7*             *12.6*        *30.2*        *37.2*        *23.4*
    Adult polycystic kidney disease       *7.8*              *6.5*             *10.2*        *14.7*        *12.3*        *17.1*
    Pyelonephritis                        *5.0*              *4.5*              *6.1*         *9.6*         *6.9*        *12.1*
    Other                                *28.8*             *26.8*             *32.4*        *20.6*        *19.8*        *21.4*

Values expressed as mean (SD); *column percent in italics.*

###### 

Numbers and rates of parathyroidectomy, per 1000 person-years, in the Swedish dialysis- and transplant population

                                       **All**   **Male**      **Female**                                                      
  ----------------------------------- --------- ---------- ------------------ ----- -------- ------------------ ----- -------- ------------------
  All                                    679      77,624     8.8 (8.1-9.4)     333   50,294    6.6 (5.9-7.4)     346   27,330   12.7 (11.4-14.0)
  Age (years)                                                                                                                           
    0-40                                 89       22,076     4.0 (3.3-5.0)     43    14,535    2.6 (2.1-3.9)     46     7540     6.1 (4.6-8.14)
    40-55                                260      25,621    10.1 (9.0-11.5)    132   16,679    7.9 (6.7-9.4)     128    8943    14.3 (12.0-17.0)
    55-70                                211      17,906    11.8 (10.3-13.5)   99    11,599    8.5 (7.0-10.4)    112    6308    17.8 (14.8-21.4)
    \> 70                                119      12,021     9.9 (8.3-11.9)    59     7481     7.9 (6.1-10.2)    60     4540    13.2 (10.3-17.0)
  Region                                                                                                                                
    North                                39        8115      4.8 (3.5-6.6)     18     5176     3.5 (2.2-5.2)     21     2940     7.1 (4.7-11.0)
    Stockholm                            116      14,337     8.0 (6.7-9.7)     51     8905     5.7 (4.3-7.5)     65     5432    12.0 (9.4-15.3)
    South-east                           76        8808      8.6 (6.9-10.8)    35     5792     6.0 (4.3-8.3)     41     3016    13.6 (10.0-18.5)
    South                                145      14,736     9.8 (8.4-11.6)    76     9994     7.6 (6.0-9.5)     69     4743    14.6 (11.5-18.4)
    Uppsala/Örebro                       147      17,267     8.5 (7.2-10.0)    80    11,211    7.1 (5.7-8.9)     67     6056    11.0 (8.7-14.0)
    West                                 153      13,613    11.2 (9.6-13.2)    71     8706     8.1 (6.5-10.3)    82     4907    16.7 (13.5-20.8)
    Abroad                                3        747       4.0 (1.3-12.5)     2     510      3.9 (1.0-15.7)     1     237      4.2 (0.6-30.0)
  Cause of renal disease                                                                                                                
    Diabetes                             101      15,984     6.3 (5.2-7.7)     47    10,385    4.5 (3.4-6.0)     54     5599     9.6 (7.4-12.6)
    Nephrosclerosis                      68       10,008     6.8 (5.4-8.6)     32     7262     4.4 (3.1-6.2)     36     2746    13.1 (9.5-18.2)
    Glomerulonephritis                   205      18,219    11.3 (9.8-12.9)    124   13,202    9.4 (7.9-11.2)    81     5018    16.1 (13.0-20.1)
    Adult polycystic kidney disease      100       9481     10.5 (8.7-12.8)    41     5156     8.0 (5.9-10.8)    59     4325    13.6 (10.6-17.6)
    Pyelonephritis                       65        4905     13.3 (10.4-16.9)   23     2784     8.3 (5.5-12.4)    42     2121    19.8 (14.6-26.8)
    Other                                140      19,018     7.4 (6.2-8.7)     66    11,496    5.7 (4.5-7.3)     74     7522     9.8 (7.8-12.4)
  Years with functioning transplant                                                                                                     
    0                                    417      43,334     9.6 (8.7-10.6)    200   27,973    7.1 (6.2-8.2)     217   15,361   14.1 (12.4-16.1)
    0 \> and \< 1                        77        3056     25.2 (20.2-31.5)   39     1964    19.9 (14.5-27.2)   38     1091    34.8 (25.3-47.8)
    ≥ 1 and \< 3                         97        8427     11.5 (9.4-14.0)    47     5503     8.5 (6.4-11.4)    50     2924    17.1 (13.0-22.6)
    ≥ 3                                  88       22,808     3.9 (3.1-4.8)     47    14,854    3.2 (2.4-4.2)     41     7953     5.2 (3.8-7.0)

After adjustment, female gender, age group 40--55 years as compared with other age groups, and non-diabetic cause of end-stage renal disease were all associated with an increased risk for PTX, Table [3](#T3){ref-type="table"}. Cumulative time with functioning renal transplant (more than one but less than three years, and more than three years as compared with zero time with functioning graft) was inversely associated with risk of PTX in the adjusted analysis, Table [3](#T3){ref-type="table"}.

###### 

Risk factors for parathyroidectomy, as incidence rate ratios (IRR), in the Swedish dialysis- and transplant population

  **Factor**                           **IRR (95% CI)**  
  ----------------------------------- ------------------ ------------------
  Gender                                                          
    Female                                   1.00               1.00
    Male                               0.53 (0.45-0.61)   0.53 (0.45-0.61)
  Age (years)                                                     
    0-40                               0.90 (0.71-1.12)   0.87 (0.69-1.09)
    40-55                                    1.00               1.00
    55-70                              0.80 (0.67-0.96)   0.78 (0.65-0.94)
    \> 70                              0.27 (0.21-0.34)   0.25 (0.19-0.32)
  Region                                                          
    Stockholm                                1.00               1.00
    North                              0.57 (0.40-0.83)   0.66 (0.46-0.94)
    South-east                         1.04 (0.78-1.39)   1.13 (0.84-1.51)
    South                              1.23 (0.97-1.58)   1.38 (1.08-1.77)
    Uppsala/Örebro                     1.00 (0.78-1.27)   1.19 (0.93-1.52)
    West                               1.37 (1.07-1.74)   1.49 (1.17-1.89)
    Abroad                             0.78 (0.25-2.47)   0.46 (0.15-1.44)
  Cause of renal disease                                          
    Diabetes                                 1.00               1.00
    Nephrosclerosis                    1.02 (0.75-1.39)   1.56 (1.14-2.13)
    Glomerulonephritis                 2.22 (1.75-2.80)   2.30 (1.80-2.94)
    Adult polycystic kidney disease    2.17 (1.65-2.87)   1.88 (1.42-2.50)
    Pyelonephritis                     2.60 (1.90-3.56)   2.54 (1.85-3.48)
    Other                              1.22 (0.98-1.60)   1.30 (1.00-1.68)
  Years with functioning transplant                               
    0                                        1.00               1.00
    0 \> and \< 1                      1.32 (1.03-1.68)   1.59 (1.23-2.04)
    ≥ 1 and \< 3                       3.22 (2.56-4.06)   0.71 (0.56-0.89)
    ≥ 3                                1.00 (0.79-1.27)   0.24 (0.19-0.30)

There were few events and person-years in the first two years the SNR was operating, 1991 and 1992, hence incidence rate ratios for those years had wide confidence intervals. In the adjusted model there were no statistically significant differences in the PTX rate from 1993 to 2000 using year 2000 as a reference year, Table [4](#T4){ref-type="table"}. The PTX rate was significantly higher in the years 2001 through 2004. In the subsequent years following year 2005, there was a decrease in the PTX rate, although this change did not reach statistical significance as compared with the reference year 2000, Figure [1](#F1){ref-type="fig"}, Table [4](#T4){ref-type="table"}. Aggregate data on the sales of cinacalcet seemed to match the decreasing rate of PTX, Figure [2](#F2){ref-type="fig"}.

###### 

Rates and incidence rate ratios (IRR) of parathyroidectomy per calendar year in the Swedish dialysis and transplant population

  **Calendar year**    **Rate/1000 person-years**   **Unadjusted IRR**   **Adjusted\* IRR**
  ------------------- ---------------------------- -------------------- --------------------
  1991                       5.2 (1.3-20.8)          0.18 (0.04-0.74)     0.45 (0.11-1.87)
  1992                       0.9 (0.1-6.6)           0.06 (0.00-0.47)     0.08 (0.01-0.60)
  1993                      10.2 (6.3-16.4)          0.82 (0.46-1.46)     0.96 (0.54-1.72)
  1994                      11.9 (8.1-17.4)          1.13 (0.68-1.88)     1.18 (0.71-1.96)
  1995                       8.8 (5.9-13.3)          0.90 (0.54-1.54)     0.94 (0.56-1.60)
  1996                      12.1 (8.7-16.7)          1.30 (0.81-2.06)     1.33 (0.83-2.11)
  1997                       9.0 (6.3-12.9)          1.00 (0.61-1.62)     1.04 (0.64-1.69)
  1998                       7.0 (4.7-10.2)          0.82 (0.50-1.37)     0.83 (0.50-1.38)
  1999                       7.1 (4.1-10.3)          0.89 (0.54-1.45)     0.87 (0.53-1.43)
  2000                       8.0 (5.8-11.2)                1.00                 1.00
  2001                      13.5 (10.6-17.3)         1.78 (1.18-2.7)      1.75 (1.16-2.64)
  2002                      13.2 (10.4-16.9)         1.75(1.16-2.64)      1.77 (1.17-2.67)
  2003                      12.4 (9.7-15.9)          1.69 (1.11-2.56)     1.70 (1.12-2.56)
  2004                      12.6 (9.9-16.0)          1.79 (1.19-2.70)     1.76 (1.17-2.65)
  2005                      10.3 (8.0-13.3)          1.45 (0.95-2.20)     1.47 (0.97-2.24)
  2006                       4.4 (3.0-6.4)           0.64 (0.39-1.07)     0.64 (0.39-1.07)
  2007                       5.4 (3.9-7.6)           0.81 (0.51-1.31)     0.82 (0.51-1.31)
  2008                       5.8 (4.2-8.0)           0.88 (0.56-1.40)     0.91 (0.57-1.44)
  2009                       5.7 (4.1-7.8)           0.88 (0.56-1.40)     0.90 (0.57-1.42)

\*Adjusted for gender, age at baseline (in categories), cause of renal disease, region, years with functioning renal transplant (in categories).

![PTX incidence rate ratio, adjusted for gender, age (in categories), region, cause of renal disease and time with functioning renal transplant (in categories).](1471-2369-15-75-1){#F1}

![Aggregated sales of cinacalcet and yearly rates of PTX/1000 person-years at risk between 2005 and 2009.](1471-2369-15-75-2){#F2}

Discussion
==========

In the present study, risk factors for PTX were female gender, age 40--55 years, and non-diabetic cause of renal disease. In the adjusted model, having had a functioning renal graft for less than one year was also associated with increased risk of PTX, whereas having had a functioning renal graft for more than one year was associated with decreased risk, compared with zero time with functioning graft.

The increased risk of PTX in women, patients in younger middle age and non-diabetics is congruent with results from previous studies \[[@B1]-[@B4]\]. The regional distribution of PTX was heterogeneous with the lowest rate in the Northern region. We believe, as was also suggested by previous authors, that lower access to specialist nephrology might account for these regional differences \[[@B2]\]. Having had a functioning renal transplant for more than a year was associated with a decreased risk of PTX in the adjusted analysis. This is to be expected, given that renal transplantation usually ameliorates sHPT \[[@B11]\].

In the present study the overall unadjusted PTX rate was 8.8 (95% CI, 8.1-9.4) per 1000 person-years, which is in line with previous investigations, reporting an incidence between 4.3 and 15.2/1000 person-years \[[@B1]-[@B5],[@B12]\].

We found no significant differences in the PTX incidence during the period 1993 to 2000 in comparison with the reference year 2000. However, from 2001 to 2004 the rate increased significantly, even after adjusting for patient characteristics, and showed a tendency to decrease from 2005 onwards. Our results are similar to the most recent study reporting change over time of PTX in sHPT by Li *et. al*. They found that the adjusted PTX rate increased in 1998, peaked in 2002 and decreased through 2005 with a new increase in 2006 and 2007 \[[@B3]\]. Malberti *et. al* showed a relatively constant PTX rate throughout the study period of 1983 and 1996 \[[@B5]\]. Kestenbaum *et. al* reported a slight rise in adjusted PTX rates between 1990 and 1995 with a subsequent decline of 30% in 1999 \[[@B1]\]. Foley *et. al* reported a progressive decline from 1992 to 1998 with an increase in 2002 \[[@B2]\].

There are several possible explanations for this reported diversity in PTX rates. Firstly, the studies cover a large span of time from 1971 to 2007 with different observational and comparison periods. Secondly, the patient cohorts studied are heterogenous, often comprising subgroups of RRT patients \[[@B1]-[@B4]\].

Our study comprises all RRT patients in Sweden and covers the period before and after key publications on the consequences of sHPT on mortality and cardiovascular risk \[[@B13]-[@B16]\] and after the publication of the KDOQI guidelines for PTX \[[@B17]\]. The increase in PTX rates after 2000 might be a consequence of these reports. After 2005 the PTX rate fell and remained lower throughout the study period. This decrease was associated in time with the introduction of paracalcitol in December 2004 and calcimimetics in 2005 in Sweden. Changes in PTX rates coincided with changes in the aggregate sale of cinacalcet during this period (Figure [2](#F2){ref-type="fig"}).

A limitation of the present study is the lack of biochemical data, such as levels of parathyroid hormone, and of information on medical treatment. Strengths include the high quality of the Swedish Renal Registry, with an almost 100% nation wide coverage and a data reporting incidence of 95% \[[@B6]\]. In addition, our follow-up period comprises different eras of treatment availability and modality. The fact that this study is based on an entire population with a wide geographical distribution within the country is to our knowledge a unique situation. We also believe that external validity was increased by including all patients on RRT, irrespective of treatment modality. The linkage of three nation-wide registries with broad and accurate coverage further adds to the validity of the present results.

Conclusion
==========

PTX rates differed over time in Swedish patients on RRT. This might reflect increasing awareness of the potential benefits of treating sHPT, and it is possible that the fall in rates from 2005 was caused by the introduction of calcimimetics. Female gender, non-diabetic cause of renal disease and age group 40--45 compared with younger and older patients, and cumulative time with functioning graft less than one year were all associated with higher risk for PTX.
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